- Paul Abrams, professor of urology
- 1Bristol Urological Institute, Southmead Hospital, Bristol BS10 5NB
- paul_abrams{at}bui.ac.uk
Drug companies market drugs for BPH (benign prostatic hyperplasia). However, this is a misuse of the term, which all dictionaries define as a histological term and not related to gross anatomical change. It is therefore disappointing that the BMJ has commissioned review articles on BPH .1 Several important organisations have accepted the arguments presented in the …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Re: How much of a social media profile can doctors have?
Published 13 February 2012
Re: Diagnosis and management of Raynaud’s phenomenon
Published 13 February 2012
Re: Is it unethical for doctors to encourage healthy adults to donate a kidney to a stranger? No
Published 13 February 2012
Re: Report predicts 20 million AIDS orphans in Africa by 2010
Published 13 February 2012
ESR adaptation for age - A forgotten pearl!
Published 13 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
How much of a social media profile can doctors have? (7 responses)
Published 23 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (7 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (7 responses)
Published 1 Feb 2012